Telix Pharmaceuticals Ltd — Call Transcript 2018

Sep 13, 2018

==> picture [143 x 79] intentionally omitted <==

Atlab Transaction – Investor Conference Call

Audio recording available

Melbourne (Australia) – 14 September 2018 . Telix Pharmaceuticals Limited (ASX.TLX) (“ Telix ”, the “ Company ”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (“ MTR ”) is pleased to provide investors an audio link to the Investor Conference Call hosted by the Company and led by Managing Director and CEO, Dr Christian Behrenbruch, on Thursday 13 September 2018.

• Investors can access the audio recording here: http://www.telixpharma.com/wp content/uploads/2018/09/Telix-Atlab-Acqusition-Conference-Call-Recording-2.mp3

Investors can access the market briefing presentation here: https://www.asx.com.au/asxpdf/20180911/pdf/43y6vx5gskj60v.pdf

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com

Telix Investor Relations (Australia)

Arthur Chan WE Buchan Tel: +61 (2) 9237 2805 Email: telix@we-buchan.com

Telix Investor Relations (US)

Lisa Wilson In-Site Communications Tel: +1 212 452 2793 Email: lwilson@insitecony.com

Page 1